CD274 and neoplasm: Recently, immunotherapies focusing on the inhibition of PD-1/PD-L1 and subsequent activation of T cells, in combination with standard of care, have resulted in improved overall survival rates in patients with SCLC15,16; however, overall outcomes for this tumor type remain limited and there remains a great unmet need to develop more effective therapeutic approaches enhancing the activity of T cells or other immune cells17.